Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Carcinoma, Hepatocellular 8Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Rectal Neoplasms 6Nasopharyngeal Carcinoma 6Melanoma 6Lymphoma, Extranodal NK-T-Cell 6Locally Advanced Rectal Cancer 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hemangiosarcoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

Gemcitabine 5Nivolumab 3Irinotecan 3Ipilimumab 3Docetaxel 3Cyclophosphamide 33-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3pegfilgrastim 2Vincristine 2Temozolomide 2Ibandronic Acid 2Everolimus 2Doxorubicin 2CTLA-4 Antigen 2spartalizumab 1saracatinib 1samarium Sm-153 lexidronam 1pembrolizumab 1palbociclib 1liposomal doxorubicin 1lenvatinib 1fludarabine 1anlotinib 1angiotensin I (1-7) 1aldesleukin 1Zoledronic Acid 1Trabectedin 1Topotecan 1Taxes 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Neoplasms × spartalizumab × Clear all
NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Assaf-Harofeh Medical Center

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡